Genetic analysis of psychosis Biotypes: shared Ancestry-adjusted polygenic risk and unique genomic associations
- PMID: 39709506
- PMCID: PMC12092190
- DOI: 10.1038/s41380-024-02876-z
Genetic analysis of psychosis Biotypes: shared Ancestry-adjusted polygenic risk and unique genomic associations
Abstract
The Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) created psychosis Biotypes based on neurobiological measurements in a multi-ancestry sample. These Biotypes cut across DSM diagnoses of schizophrenia, schizoaffective disorder, and bipolar disorder with psychosis. Two recently developed post hoc ancestry adjustment methods of Polygenic Risk Scores (PRSs) generate Ancestry-Adjusted PRSs (AAPRSs), which allow for PRS analysis of multi-ancestry samples. Applied to schizophrenia PRS, we found the Khera AAPRS method to show superior portability and comparable prediction accuracy as compared with the Ge method. The three Biotypes of psychosis disorders had similar AAPRSs across ancestries. In genomic analysis of Biotypes, 12 genes, and isoforms showed significant genomic associations with specific Biotypes in a Transcriptome-Wide Association Study (TWAS) of genetically regulated expression (GReX) in the adult brain and fetal brain. TWAS inflation was addressed by the inclusion of genotype principal components in the association analyses. Seven of these 12 genes/isoforms satisfied Mendelian Randomization (MR) criteria for putative causality, including four genes TMEM140, ARTN, C1orf115, CYREN, and three transcripts ENSG00000272941, ENSG00000257176, ENSG00000287733. These genes are enriched in the biological pathways of Rearranged during Transfection (RET) signaling, Neural Cell Adhesion Molecule 1 (NCAM1) interactions, and NCAM signaling for neurite out-growth. The specific associations with Biotypes suggest that pharmacological clinical trials and biological investigations might benefit from analyzing Biotypes separately.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: CX: None. NA-R: None. CAT: B-SNIP Diagnostics, Board of Managers; Kynexis, Scientific Advisory Board and retainer; Merck DSMB; Neuventis, Board, own stock. MSK: B-SNIP Diagnostics, Board of Managers; Advisor to Alkermes. GDP: B-SNIP Diagnostics, Board of Managers. SKK: B-SNIP Diagnostics, Board of Managers. BC: B-SNIP Diagnostics, Board of Managers; Kynexis Corporation, Scientific Advisory Board. JEM: B-SNIP Diagnostics, Board of Managers. DP: None. RL: None. SKH: None. JRB: None. EII: B-SNIP Diagnostics, Board of Managers. CW: None. RD: None. CC: None. CL: None. ESG: B-SNIP Diagnostics, Board of Managers; Consultant: Kynexis Corporation. Ethics approval and consent to participate: All methods were performed in accordance with the relevant guidelines and regulations. B-SNIP recruitment sites were in Athens GA (the University of Georgia and Augusta University Medical College of Georgia), Baltimore MD (Maryland Psychiatric Research Center), Boston MA (Beth Israel Deaconess Medical Center), Chicago IL (the University of Illinois-Chicago and University of Chicago), Dallas TX (UT Southwestern Medical Center), Detroit MI (Wayne State University), and Hartford CT (Institute of Living). All recruitments, interviews, and laboratory data collections were completed at those locations. The Institutional Review Board at participating institutions approved the projects; all participants provided informed consent prior to involvement.
Update of
-
Genetic Analysis of Psychosis Biotypes: Shared Ancestry-Adjusted Polygenic Risk and Unique Genomic Associations.medRxiv [Preprint]. 2024 Dec 8:2024.12.05.24318404. doi: 10.1101/2024.12.05.24318404. medRxiv. 2024. Update in: Mol Psychiatry. 2025 Jun;30(6):2673-2685. doi: 10.1038/s41380-024-02876-z. PMID: 39677452 Free PMC article. Updated. Preprint.
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous